SkylineDx study highlights value in combined myeloma diagnostic approach
SkylineDx’s SKY92 test with fluorescence in situ hybridisation testing led to more accurate identification of high-risk ...
SKYLINEDX ANNOUNCES NEW PUBLICATION ON SKY92 GENE EXPRESSION PROFILING TEST in DEFINING ULTRA-HIGH-RISK MULTIPLE MYELOMA
SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announces the publication of ...
WFMZ-TV15d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
WFMZ-TV16d
Teenagers who think they’re fat more likely to consider self-harm: study
Teenagers who perceive themselves as overweight are three times more likely to consider self-harming, warns new research. The heightened risk is present regardless of whether the youngster is ...
Morningstar1mon
BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco
Morningstar brands and products Company Portfolio ...
Malaysian Reserve1y
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
MelaNodal Predict is a lab-developed test validated by Quest Diagnostics and based on technology developed by SkylineDx, an oncology biotechnology company, alongside Mayo Clinic. The technology ...
Malaysian Reserve7y
Is the Fastest-Growing Segment of the Art Market the Cheapest?
IN JUNE 2017, Heritage Auctions decided to increase the number of its prints and multiples auctions from four times a year to once a month. It had been holding live and online auctions in the category ...